Ryan J. Sullivan, MD

Articles

Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma

November 23rd 2019

Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.

Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

July 5th 2019

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Sullivan on Immunotherapy Approaches in Melanoma

April 29th 2019

Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma.

Dr. Sullivan on Findings From the ENCORE 601 Trial in Melanoma

April 10th 2019

Ryan J. Sullivan, MD, instructor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital (MGH), MGH Cancer Center, discusses findings from the ENCORE 601 trial in melanoma.

Dr. Sullivan on Considerations for Treatment in Metastatic Melanoma

February 28th 2019

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses considerations for initial treatment of patients with metastatic melanoma.

Dr. Sullivan Discusses the Current Treatment of Melanoma

April 4th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses the current treatment of patients with melanoma.

Dr. Sullivan on Targeted Therapy for BRAF-Mutant Melanoma

February 20th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses novel molecular targets in patients with melanoma.

Dr. Ryan Sullivan on Treatment Options for Advanced Basal Cell Carcinoma

July 8th 2016